

Daphne A Haas-Kogan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3534272/publications.pdf>

Version: 2024-02-01

125
papers

5,499
citations

126907

33
h-index

88630

70
g-index

128
all docs

128
docs citations

128
times ranked

8277
citing authors

#	ARTICLE	IF	CITATIONS
1	Update on Radiation Therapy for Central Nervous System Tumors. <i>Hematology/Oncology Clinics of North America</i> , 2022, 36, 77-93.	2.2	5
2	Frequency, etiologies, risk factors, and sequelae of falls among patients with brain metastases: a population- and institutional-level analysis. <i>Neuro-Oncology Practice</i> , 2022, 9, 114-122.	1.6	1
3	Patient specific distortion detection and mitigation in MR images used for stereotactic radiosurgery. <i>Physics in Medicine and Biology</i> , 2022, 67, 065009.	3.0	2
4	Predictors of long-term survival among patients with brain metastases. <i>Neuro-Oncology</i> , 2022, , .	1.2	2
5	A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 143-151.	0.8	7
6	Breast and Cervical Cancer Screening Disparities in Transgender People. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 116-121.	1.3	14
7	Trends in location of death for individuals with primary brain tumors in the United States. <i>Neuro-Oncology</i> , 2022, 24, 1400-1401.	1.2	2
8	“Per protocol” practice patterns for Children's Oncology Group trials within the radiation oncology community. <i>Pediatric Blood and Cancer</i> , 2022, , e29673.	1.5	0
9	DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. <i>Journal of Neuro-Oncology</i> , 2022, 157, 499-510.	2.9	2
10	LGG-52. Volumetry-based response characterization of recurrent pediatric low-grade gliomas in PNOG clinical Neuro-oncology trials. <i>Neuro-Oncology</i> , 2022, 24, i100-i100.	1.2	0
11	Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children's Oncology Group phase I consortium study. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	2
12	Population-based estimates of survival among elderly patients with brain metastases. <i>Neuro-Oncology</i> , 2021, 23, 661-676.	1.2	25
13	A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 726-735.	0.8	29
14	Prostate Cancer Screening Patterns Among Sexual and Gender Minority Individuals. <i>European Urology</i> , 2021, 79, 588-592.	1.9	31
15	Gliomas, germ cell tumors, and craniopharyngioma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28401.	1.5	5
16	Seizures Among Patients With Brain Metastases. <i>Neurology</i> , 2021, 96, .	1.1	12
17	Clinical Characteristics, Experiences, and Outcomes of Transgender Patients With Cancer. <i>JAMA Oncology</i> , 2021, 7, e205671.	7.1	23
18	Feasibility of hippocampal avoidance whole brain radiation in patients with hippocampal involvement: Data from a prospective study. <i>Medical Dosimetry</i> , 2021, 46, 21-28.	0.9	4

#	ARTICLE	IF	CITATIONS
19	Lipidome-based Targeting of STAT3-driven Breast Cancer Cells Using Poly-L-glutamic Acid-coated Layer-by-Layer Nanoparticles. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 726-738.	4.1	4
20	Assessment of Simulated SARS-CoV-2 Infection and Mortality Risk Associated With Radiation Therapy Among Patients in 8 Randomized Clinical Trials. <i>JAMA Network Open</i> , 2021, 4, e213304.	5.9	4
21	DDRE-32. THERAPEUTIC TARGETING OF A NOVEL METABOLIC ADDICTION IN DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology Advances</i> , 2021, 3, i13-i13.	0.7	0
22	Long-term outcomes of pediatric and young adult patients receiving radiotherapy for nonmalignant vascular anomalies. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28955.	1.5	1
23	Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. <i>Neuro-Oncology</i> , 2021, 23, 1872-1884.	1.2	48
24	Emergency department visits and inpatient hospitalizations among older patients with brain metastases: a dual population- and institution-level analysis. <i>Neuro-Oncology Practice</i> , 2021, 8, 569-580.	1.6	1
25	HGG-38. DE NOVO PYRIMIDINE SYNTHESIS INHIBITION INDUCES REPLICATION CATASTROPHE MEDIATED CELL DEATH IN DIFFUSE MIDLINE GLIOMA. <i>Neuro-Oncology</i> , 2021, 23, i25-i25.	1.2	0
26	Harnessing Lactate Metabolism for Radiosensitization. <i>Frontiers in Oncology</i> , 2021, 11, 672339.	2.8	11
27	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 3506-3514.	1.6	38
28	Clinical outcomes for pediatric patients receiving radiotherapy for solid tumor central nervous system metastases. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29331.	1.5	1
29	Anatomic patterns of relapse and progression following treatment with 131 I-MIBG in relapsed or refractory neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2021, , e29396.	1.5	1
30	Peripheral Blood Transcript Signatures after Internal 131I-MIBG Therapy in Relapsed and Refractory Neuroblastoma Patients Identifies Early and Late Biomarkers of Internal 131I Exposures. <i>Radiation Research</i> , 2021, 197, .	1.5	4
31	Reirradiation practices for children with diffuse intrinsic pontine glioma. <i>Neuro-Oncology Practice</i> , 2021, 8, 68-74.	1.6	8
32	Gender, Productivity, and Philanthropic Fundraising in Academic Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1401-1406.	4.9	2
33	Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. <i>Neuro-Oncology Practice</i> , 2020, 7, 4-10.	1.6	11
34	Utility of claims data for identification of date of diagnosis of brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 575-576.	1.2	12
35	Cooperative Blockade of PKC ζ and JAK2 Drives Apoptosis in Glioblastoma. <i>Cancer Research</i> , 2020, 80, 709-718.	0.9	19
36	Germline MUTYH Mutation in a Pediatric Cancer Survivor Developing a Secondary Malignancy. <i>Journal of Pediatric Hematology/Oncology</i> , 2020, 42, e647-e654.	0.6	2

#	ARTICLE	IF	CITATIONS
37	Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases. <i>Cancer</i> , 2020, 126, 5274-5282.	4.1	19
38	Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children's Oncology Group Trials. <i>JAMA Oncology</i> , 2020, 6, 1465.	7.1	26
39	Practice patterns and recommendations for pediatric image-guided radiotherapy: A Children's Oncology Group report. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28629.	1.5	11
40	Utility of claims data for delineation of intracranial treatment among patients with brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 1547-1548.	1.2	2
41	Artificial intelligence in radiation oncology. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 771-781.	27.6	167
42	What HIV/AIDS Taught Me About Pandemics: A Clinician's Perspective. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 346-347.	0.8	2
43	Treating the SARS-CoV-2 positive patient with cancer: A proposal for a pragmatic and transparent ethical process. <i>Cancer</i> , 2020, 126, 3896-3899.	4.1	5
44	Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 2741-2752.	1.6	36
45	Prescription of memantine during non-stereotactic, brain-directed radiation among patients with brain metastases: a population-based study. <i>Journal of Neuro-Oncology</i> , 2020, 148, 509-517.	2.9	7
46	Hospice Utilization in Elderly Patients With Brain Metastases. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1251-1258.	6.3	7
47	Racial disparities in supportive medication use among older patients with brain metastases: a population-based analysis. <i>Neuro-Oncology</i> , 2020, 22, 1339-1347.	1.2	27
48	Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). <i>Clinical Cancer Research</i> , 2020, 26, 1213-1219.	7.0	38
49	Mechanisms and therapeutic implications of hypermutation in gliomas. <i>Nature</i> , 2020, 580, 517-523.	27.8	374
50	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii43-ii44.	1.2	3
51	PATH-12. TEMOZOLOMIDE-INDUCED HYPERMUTATION IS ASSOCIATED WITH HIGH-GRADE TRANSFORMATION, DISTANT RECURRENCE AND REDUCED SURVIVAL IN INITIALLY LOW GRADE IDH-MUTANT GLIOMAS. <i>Neuro-Oncology</i> , 2020, 22, ii166-ii166.	1.2	2
52	EPCT-01. PHASE I STUDY OF DAY101 (TAK580) IN CHILDREN AND YOUNG ADULTS WITH RADIOGRAPHICALLY RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA (LGG). <i>Neuro-Oncology</i> , 2020, 22, iii304-iii304.	1.2	4
53	GCT-33. A PHASE 2 TRIAL OF RESPONSE-BASED RADIATION THERAPY FOR PATIENTS WITH LOCALIZED CENTRAL NERVOUS SYSTEM GERM CELL TUMORS: A CHILDREN'S ONCOLOGY GROUP (COG) STUDY. IMPACT OF RAPID CENTRAL RADIOTHERAPY REVIEW ON RADIOTHERAPY QUALITY AND PATTERN OF FAILURE FOR NON-GERMINOMATOUS GERM CELL TUMORS. <i>Neuro-Oncology</i> , 2020, 22, iii334-iii334.	1.2	0
54	DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS). <i>Neuro-Oncology</i> , 2020, 22, iii297-iii297.	1.2	0

#	ARTICLE	IF	CITATIONS
55	DIPG-01. REIRRADIATION PRACTICES FOR DIFFUSE INTRINSIC PONTINE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii287-iii287.	1.2	0
56	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2020, 22, ii44-ii44.	1.2	5
57	DDRE-12. PNOC001 (NCT01734512): A PHASE II STUDY OF EVEROLIMUS FOR RECURRENT OR PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMAS (pLGG). <i>Neuro-Oncology</i> , 2020, 22, ii63-ii64.	1.2	1
58	CTNI-19. PHASE I TRIAL OF DAY101 IN PEDIATRIC PATIENTS WITH RADIOGRAPHICALLY RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA (LGG). <i>Neuro-Oncology</i> , 2020, 22, ii46-ii46.	1.2	7
59	Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. <i>Nature Communications</i> , 2019, 10, 3731.	12.8	45
60	A Central Role of Radiation Therapy in Central Nervous System Germinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 970-971.	0.8	0
61	THER-34. MEK BLOCKADE SYNERGISTICALLY INCREASES THE ANTI-TUMOR EFFECTS OF mTOR INHIBITION IN GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, ii121-ii121.	1.2	0
62	Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 746.	7.4	220
63	Revisiting the Role of Radiation Therapy for Pediatric Low-Grade Glioma. <i>Journal of Clinical Oncology</i> , 2019, 37, 3335-3339.	1.6	21
64	Brainstem Injury in Pediatric Patients Receiving Posterior Fossa Photon Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1034-1042.	0.8	16
65	The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. <i>Nature Communications</i> , 2019, 10, 442.	12.8	86
66	DIPG-12. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs). <i>Neuro-Oncology</i> , 2019, 21, ii70-ii71.	1.2	0
67	DIPG-24. DIFFUSE INTRINSIC PONTINE GLIOMAS EXHIBIT HIGH BASAL DNA DAMAGE AND ARE VULNERABLE TO INHIBITION OF DNA DAMAGE REPAIR PATHWAYS. <i>Neuro-Oncology</i> , 2019, 21, ii73-ii74.	1.2	0
68	Towards a standard of care in oncology for transgender patients. <i>Lancet Oncology</i> , The, 2019, 20, 331-333.	10.7	7
69	Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27736.	1.5	8
70	Breast cancer subtype and intracranial recurrence patterns after brain-directed radiation for brain metastases. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 171-179.	2.5	15
71	Local control after brain-directed radiation in patients with cystic versus solid brain metastases. <i>Journal of Neuro-Oncology</i> , 2019, 142, 355-363.	2.9	13
72	Risk stratification by somatic mutation burden in Ewing sarcoma. <i>Cancer</i> , 2019, 125, 1357-1364.	4.1	18

#	ARTICLE	IF	CITATIONS
73	Management of pediatric low-grade glioma. <i>Current Opinion in Pediatrics</i> , 2019, 31, 21-27.	2.0	87
74	Neurosurgical Resection and Stereotactic Radiation Versus Stereotactic Radiation Alone in Patients with a Single or Solitary Brain Metastasis. <i>World Neurosurgery</i> , 2019, 122, e1557-e1561.	1.3	17
75	Clinical Impact of Tumor Mutational Burden in Neuroblastoma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 695-699.	6.3	29
76	National Cancer Institute Workshop on Proton Therapy for Children: Considerations Regarding Brainstem Injury. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 152-168.	0.8	138
77	Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27023.	1.5	31
78	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. <i>Radiotherapy and Oncology</i> , 2018, 126, 511-518.	0.6	18
79	The Future of Radiobiology. <i>Journal of the National Cancer Institute</i> , 2018, 110, 329-340.	6.3	76
80	Large Vessel Arteriopathy After Cranial Radiation Therapy in Pediatric Brain Tumor Survivors. <i>Journal of Child Neurology</i> , 2018, 33, 359-366.	1.4	27
81	The Children's Oncology Group Radiation Oncology Discipline: 15 Years of Contributions to the Treatment of Childhood Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 860-874.	0.8	34
82	Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 347-354.	4.1	22
83	HGG-36. NF κ B AND FOXM1 MEDIATE ANTI-CANCER ACTIVITY OF DUAL HDAC AND PI3K INHIBITION IN PEDIATRIC HIGH GRADE GLIOMA AND DIPG. <i>Neuro-Oncology</i> , 2018, 20, i96-i97.	1.2	0
84	Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. <i>Journal of Neuro-Oncology</i> , 2018, 140, 629-638.	2.9	44
85	Dual HDAC and PI3K Inhibition Abrogates NF κ B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. <i>Cancer Research</i> , 2018, 78, 4007-4021.	0.9	60
86	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	1.2	73
87	Pediatric high-grade glioma: biologically and clinically in need of new thinking. <i>Neuro-Oncology</i> , 2017, 19, now101.	1.2	217
88	Histopathologic review of pineal parenchymal tumors identifies novel morphologic subtypes and prognostic factors for outcome. <i>Neuro-Oncology</i> , 2017, 19, 78-88.	1.2	51
89	Patterns of Relapse in High-Risk Neuroblastoma Patients Treated With and Without Total Body Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 270-277.	0.8	20
90	Peripheral Blood Biomarkers Associated With Toxicity and Treatment Characteristics After ¹³¹ I-Metaiodobenzylguanidine Therapy in Patients With Neuroblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 468-475.	0.8	6

#	ARTICLE	IF	CITATIONS
91	Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. <i>Neuro-Oncology</i> , 2017, 19, 1511-1521.	1.2	483
92	Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 208-216.	1.6	100
93	A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma. <i>Cancer Cell</i> , 2017, 31, 424-435.	16.8	138
94	Brain Metastases in Newly Diagnosed Breast Cancer. <i>JAMA Oncology</i> , 2017, 3, 1069.	7.1	224
95	Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. <i>Translational Research</i> , 2017, 188, 27.e1-27.e14.	5.0	12
96	Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients. <i>Journal of Neuro-Oncology</i> , 2017, 131, 359-368.	2.9	13
97	Reply to J. Stenman et al. <i>Journal of Clinical Oncology</i> , 2017, 35, 1966-1967.	1.6	1
98	A Cautionary Tale: Risks of Radiation Therapy De-Escalation in Pediatric Malignancies. <i>Journal of Clinical Oncology</i> , 2017, 35, 2471-2472.	1.6	8
99	Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. <i>Oncotarget</i> , 2017, 8, 84697-84713.	1.8	38
100	PNR-17HIGH-DOSE CHEMOTHERAPY WITH STEM CELL TRANSPLANT TO DELAY RADIATION IN PEDIATRIC EMBRYONAL BRAIN TUMOR PATIENTS. <i>Neuro-Oncology</i> , 2016, 18, iii10.1-iii10.	1.2	0
101	ACTR-32. A PROSPECTIVE PHASE II STUDY OF EVEROLIMUS FOR RECURRENT ADULT LOW GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2016, 18, vi8-vi9.	1.2	0
102	Therapeutic radiation and the potential risk of second malignancies. <i>Cancer</i> , 2016, 122, 1809-1821.	4.1	85
103	Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas. <i>Future Oncology</i> , 2016, 12, 1493-1506.	2.4	18
104	Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. <i>Journal of Neuro-Oncology</i> , 2016, 126, 385-393.	2.9	31
105	Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. <i>Journal of Neuro-Oncology</i> , 2016, 126, 193-200.	2.9	45
106	Medical Student Perspectives on a Multi-institutional Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 217-219.	0.8	13
107	Long-term side effects of radiotherapy for pediatric localized neuroblastoma. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 604-612.	2.0	32
108	Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 2715-2721.	7.0	62

#	ARTICLE	IF	CITATIONS
109	Quality improvement of International Classification of Diseases, 9th revision, diagnosis coding in radiation oncology: Single-institution prospective study at University of California, San Francisco. <i>Practical Radiation Oncology</i> , 2015, 5, e45-e51.	2.1	4
110	Non-Muscle Myosin IIa Heavy Chain Links Squamous-Cell Carcinoma of the Head and Neck to the DNA Damage Response. <i>Frontiers in Oncology</i> , 2014, 4, 228.	2.8	1
111	Targeting Wee1 for the treatment of pediatric high-grade gliomas. <i>Neuro-Oncology</i> , 2014, 16, 352-360.	1.2	102
112	Toward an Improved Understanding of the Ionizing Radiation Induced DNA Damage/Response Networks in Human Malignancies. <i>Frontiers in Oncology</i> , 2014, 4, 335.	2.8	0
113	Preface. <i>Seminars in Radiation Oncology</i> , 2014, 24, 233-234.	2.2	0
114	Standardization and Quality Assurance of Radiation Therapy Volumes for Adults With High-Grade Gliomas. <i>Seminars in Radiation Oncology</i> , 2014, 24, 259-264.	2.2	7
115	In Reply to Bull et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 434.	0.8	0
116	Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. <i>Lancet Oncology</i> , 2013, 14, 999-1008.	10.7	246
117	Molecular targets and mechanisms of radiosensitization using DNA damage response pathways. <i>Future Oncology</i> , 2013, 9, 219-233.	2.4	62
118	The Combination of Novel Targeted Molecular Agents and Radiation in the Treatment of Pediatric Gliomas. <i>Frontiers in Oncology</i> , 2013, 3, 110.	2.8	31
119	PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. <i>Neuro-Oncology</i> , 2012, 14, 1146-1152.	1.2	85
120	Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms. <i>Cancer Letters</i> , 2011, 306, 223-229.	7.2	66
121	Vorinostat Increases Expression of Functional Norepinephrine Transporter in Neuroblastoma <i>In Vitro</i> and <i>In Vivo</i> Model Systems. <i>Clinical Cancer Research</i> , 2011, 17, 2339-2349.	7.0	61
122	Long-Term Results for Children With High-Risk Neuroblastoma Treated on a Randomized Trial of Myeloablative Therapy Followed by 13- <i>cis</i> -Retinoic Acid: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1007-1013.	1.6	768
123	Radiation-induced gliomas. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1511-1517.	2.8	52
124	Biomarkers to Predict Response to Epidermal Growth Factor Receptor Inhibitors. <i>Cell Cycle</i> , 2005, 4, 1369-1372.	2.6	69
125	Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 28-39.	0.8	149